Hepatic Pathology among Patients without Known Liver Disease Undergoing Bariatric Surgery: Observations and a Perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) Study

David E. Kleiner; Paul D. Berk; Jesse Y. Hsu; Anita P. Courcoulas; David Flum; Saurabh Khandelwal; John Pender; Alfons Pomp; James Roerig; Laura L. Machado; Bruce M. Wolfe; Steven H. Belle; for the LABS Consortium

doi:10.1055/s-0034-1371083

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2014; 34(01): 098-107
DOI: 10.1055/s-0034-1371083

Editors' Choice

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hepatic Pathology among Patients without Known Liver Disease Undergoing Bariatric Surgery: Observations and a Perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) Study

David E. Kleiner

¹Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland

,

Paul D. Berk

²Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York

,

Jesse Y. Hsu

³University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania

,

Anita P. Courcoulas

⁴Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

,

David Flum

⁵Department of Surgery, University of Washington, Seattle, Washington

,

Saurabh Khandelwal

⁵Department of Surgery, University of Washington, Seattle, Washington

,

John Pender

⁶Department of Surgery, East Carolina University, Greenville, North Carolina

,

Alfons Pomp

⁷Department of Surgery, Weill Cornell Medical College, New York, New York

,

James Roerig

⁸Neuropsychiatric Research Institute, University of North Dakota, Fargo, North Dakota

,

Laura L. Machado

⁹Sacramento Bariatric Medical Associates, Sacramento, California

,

Bruce M. Wolfe

¹⁰Division of General Surgery, Oregon Health and Science University, Oregon Weight Loss Surgery, Portland, Oregon

,

Steven H. Belle

³University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania

,

for the LABS Consortium

› Author Affiliations

Abstract

Liver biopsy is not routine during bariatric surgery. Alanine aminotransferase (ALT) is widely used to screen for liver disease. We assessed the relationship between ALT and pathology in biopsies from Longitudinal Assessment of Bariatric Surgery (LABS) patients with normal preoperative ALTs. Biopsies from the LABS-1 and LABS-2 studies were scored using the NASH CRN and Ishak systems. Diagnosis and histology were examined in relation to alanine aminotransferase (ALT) values. Six-hundred ninety-three suitable biopsies were evaluated. Biopsied patients had a median age of 45 years; 78.6% were female and 35.1% diabetic; median body mass index was 46 kg/m². Six-hundred thirty-five biopsied patients had preoperative ALTs. Median ALT was 25 IU/L (interquartile range [IQR] 19–36 IU/L); 26.6% had an ALT > 35 IU/L and 29.9% exceeded the more restrictive Prati criteria for normal. Using the Prati criteria, 7.9% of participants with normal ALT had steatohepatitis and 5.3% had ≥ stage 2 fibrosis. Logistic regression models were used to predict the probabilities of having bridging fibrosis/cirrhosis or a diagnosis of borderline/definite steatohepatitis in the unbiopsied LABS-2 sample. The proportion of biopsied participants with these findings was very similar to the modeled results from the unbiopsied cohorts. We estimated that 86.0% of participants with advanced fibrosis and 88.1% of participants with borderline/definite steatohepatitis were not biopsied and went undiagnosed. As ALT did not reliably exclude significant obesity-related liver disease in bariatric surgery patients, consideration should be given to routine liver biopsy during bariatric surgery and medical follow-up of significant hepatic pathology.

Keywords

bariatric surgery - liver biopsy - NAFLD - steatohepatitis - cirrhosis

Full Text

References

References
1 Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307 (5) 491-497
2 Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288 (14) 1723-1727
3 Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295 (13) 1549-1555
4 Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 2007; 132 (6) 2087-2102
5 Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 (Suppl. 01) S5-S10
6 Younossi ZM, Stepanova M, Afendy M , et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9 (6) 524-530 , e1, quiz e60
7 Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012; 27 (10) 1555-1560
8 Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89 (6) 2583-2589
9 Brunt EM, Kleiner DE, Wilson LA , et al; NASH Clinical Research NetworkA list of members of the Nonalcoholic Steatohepatitis Clinical Research Network can be found in the Appendix. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49 (3) 809-820
10 Brunt EM, Tiniakos DG. Pathological features of NASH. Front Biosci 2005; 10: 1475-1484
11 Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32 (1) 3-13
12 Kleiner DE, Brunt EM, Van Natta M , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (6) 1313-1321
13 Zelman S. The liver in obesity. AMA Arch Intern Med 1952; 90 (2) 141-156
14 Thaler H. Morphologische befunde bei chronischer alkoholintoxikation [Morphologic findings in chronic alcohol intoxication]. In: Gerok W, Sickinger K, Hennkeuser HH, , eds. Alcohol and the Liver. Stuttgart, Germany: Schattauer Verlag; 1971: 257-265
15 Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55 (7) 434-438
16 Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11 (1) 74-80
17 Viral Hepatitis Surveillance – United States. 2010. Centers for Disease Control; 2012.
18 Centers for Disease Control. Reported cases of acute viral hepatitis, by type and year, United States, 1966–2003. Atlanta, GA: Centers for Disease Control; 2012
19 Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013; 58 (1) 428-438
20 Lawitz E, Poordad F, Kowdley KV , et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 2013; 59 (1) 18-23
21 Pawlotsky JM. Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 2013; 369: 321-342
22 Vachon ML, Dieterich DT. The era of direct-acting antivirals has begun: the beginning of the end for HCV?. Semin Liver Dis 2011; 31 (4) 399-409
23 Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004; 4 (5) 686-693
24 Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141 (4) 1249-1253
25 Merion RM. Current status and future of liver transplantation. Semin Liver Dis 2010; 30 (4) 411-421
26 Sanyal AJ, Chalasani N, Kowdley KV , et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362 (18) 1675-1685
27 Speliotes EK, Yerges-Armstrong LM, Wu J , et al; NASH CRN; GIANT Consortium; MAGIC Investigators; GOLD Consortium. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7 (3) e1001324
28 Belle S, Consortium L ; LABS Consortium. The NIDDK Bariatric Surgery clinical Research Consortium (LABS). Surg Obes Relat Dis 2005; 1 (2) 145-147
29 Prati D, Taioli E, Zanella A , et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137 (1) 1-10
30 Belle SH, Berk PD, Courcoulas AP , et al; Longitudinal Assessment of Bariatric Surgery Consortium Writing Group. Safety and efficacy of bariatric surgery: Longitudinal Assessment of Bariatric Surgery. Surg Obes Relat Dis 2007; 3 (2) 116-126
31 Flum DR, Belle SH, King WC , et al; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361 (5) 445-454
32 Belle SH, Berk PD, Chapman WH , et al; LABS Consortium. Baseline characteristics of participants in the Longitudinal Assessment of Bariatric Surgery-2 (LABS-2) study. Surg Obes Relat Dis 2013; 9 (6) 926-935 [Epub ahead of print]
33 Ishak K, Baptista A, Bianchi L , et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22 (6) 696-699
34 Bedossa P, Poitou C, Veyrie N , et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56 (5) 1751-1759
35 Kral JG, Thung SN, Biron S , et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135 (1) 48-58
36 Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005; 42 (3) 650-656
37 Mofrad P, Contos MJ, Haque M , et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37 (6) 1286-1292
38 Chalasani N, Younossi Z, Lavine JE , et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55 (6) 2005-2023
39 Dolce CJ, Russo M, Keller JE , et al. Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery. Surg Obes Relat Dis 2009; 5 (3) 323-328
40 Teixeira AR, Bellodi-Privato M, Carvalheira JB, Pilla VF, Pareja JC, D'Albuquerque LA. The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory. Obes Surg 2009; 19 (12) 1678-1684
41 Neuschwander-Tetri BA, Unalp A, Creer MH ; Nonalcoholic Steatohepatitis Clinical Research Network. Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels. Arch Intern Med 2008; 168 (6) 663-666
42 Verna EC, Berk PD. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. Semin Liver Dis 2008; 28 (4) 407-426